Physician profile
Laura E Thomas
NPI 1144573890
$9,954.71
in general payments reported to CMS, 2019-2025
29 companies · $648 in 2025
The $648 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,592 · 2022: $1,331 · 2023: $1,290 · 2024: $5,093 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,523 · Food and Beverage: $3,438 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,523.09 |
| Food and Beverage | $3,438.05 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,924.66 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Navitor |
| Novartis Pharmaceuticals Corporation | $970.23 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $618.81 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $498.98 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $487.31 | 2021-2025 | Onpattro, Amvuttra |
| Astrazeneca Pharmaceuticals Lp | $392.18 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Amgen INC. | $348.67 | 2021-2024 | Repatha |
| Pfizer INC. | $270.38 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $221.03 | 2021-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $187.11 | 2021-2025 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $167.56 | 2023-2025 | Lifevest |
| Scpharmaceuticals INC. | $125.88 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.07 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $83.73 | 2023-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $80.25 | 2021-2023 | Nexletol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $59.18 | 2021-2025 | |
| Medtronic, INC. | $58.63 | 2022-2024 | Corevalve Evolut R |
| Regeneron Healthcare Solutions, INC. | $41.76 | 2024-2025 | Evkeeza |
| Boston Scientific Corporation | $39.82 | 2022-2024 | Watchman Flx |
| Cvrx, INC. | $39.65 | 2024 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $37.22 | 2025 | Optimizer |
| Kowa Pharmaceuticals America, INC. | $32.30 | 2021-2022 | |
| Edwards Lifesciences Corporation | $31.06 | 2025 | Sapien 3 Ultra Resilia |
| Lexicon Pharmaceuticals, INC. | $29.20 | 2024 | |
| Chiesi USA, INC. | $28.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.44 | 2023-2024 | |
| Amarin Pharma, INC. | $17.95 | 2022 | |
| Novo Nordisk INC | $17.57 | 2025 | Wegovy |
| United Therapeutics Corporation | $16.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.